Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-09-26

FDA Approved: LUMRYZ — Supplemental Application (Avadel CNS Pharmaceuticals, LLC)

View source ↗

Summary

The FDA approved a supplemental application for LUMRYZ (sodium oxybate) submitted by Avadel CNS Pharmaceuticals, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LUMRYZ (Sodium oxybate)

Snippet

SUPPL AP for LUMRYZ (SODIUM OXYBATE)